Dear Editor, Acquired haemophilia A is a rare but potentially lifethreatening bleeding disorder caused by autoantibodies against the coagulation factor (F) VIII (FVIII inhibitor) which is in some cases associated with autoimmune diseases, solid tumours, haemotologic malignancies or can occur in the post-partum period. For further information concerning the pathophysiology of acquired haemophilia, please refer to [1] .
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Mortality is rather high in newly diagnosed acquired haemophilia ranging from 8% to 22% in different studies [2] [3] [4] [5] . A major cause of significant mortality and morbidity is the frequent confusion with other life-threatening conditions such as disseminated intravascular coagulation, thus often leading to uncontrolled bleeding prior to correct diagnosis of the disease.
Effective treatment involves not only the initial treatment of acute haemorrhage with factor VIII concentrates, a factor-VIII-bypassing-agent such as recombinant FVIIa or activated prothrombin complex concentrate but also the eradication of the inhibitor by immunosuppression, plasmapheresis or immunoadsorption or a combination of these modalities [1, 5, 6] .
A 45-year-old man with known and untreated chronic discoid lupus erythematodes presented to a district hospital with rapidly worsening pain in his left lower limb without any traumatic event. A soft tissue haemorrhage (compartment syndrome) was diagnosed by clinical examination and ultrasound. Neither the patient's history nor his family history gave evidence for bleeding disorders. Laboratory findings revealed an isolated prolonged activated partial thromboplastin time (aPTT) with a normal prothrombin time (PT), a normal platelet count and a reduced haemoglobin level. After repeated unsuccessful surgical treatment and recurrence of the severe tissue haematoma, the patient was referred to the University Hospital of Muenster. The coagulation work-up revealed a tremendously reduced level of FVIII activity (<1%), which did not normalise in mixing assay. The FVIII inhibitor titer was 6 Bethesda Units per mL (BU/mL) initially. All other levels of coagulation factors were within the normal range. Computed tomography of thorax and abdomen did not give any evidence for an underlying malignancy. Furthermore, a systemic autoimmune disease could be excluded by further laboratory tests such as anti-ds-DNA, ANA and ANCA.
Immediate administration of high-dose rFVIIa (Novoseven®, 130 μg/kg bodyweight, 960 kIE abs.) was followed by emergency surgery and subsequent immunoadsorption with a protein A column in order to rapidly reduce the inhibitor level. Besides immunoadsorption, the immunosuppressive regimen consisted of prednisolone (100 mg daily) and cyclophosphamide (100 mg daily). The anticoalugant regime during immunoadsorption consisted of heparin (2,000 IE/h) and ACDA. The repeated infusion of rFVIIa (Novoseven®, 50 μg/kg bodyweight, (360 kIE)) initially six times per day for 3 days, then three times per day for 4 days) controlled bleeding. The cumulative dose of rFVIIa given was 16,600 kIE or 2.3 mg/kg bodyweight. Immunoadsorption was performed daily for a total of 5 days and rVIIa was given for 7 days with gradually prolonging the time interval. Under this regimen, the FVIII inhibitor titer declined to 1.5 BU so that haemostatic treatment was switched from rFVIIa to rFVIII (Advate®, 1,000 IE three times daily) thus achieving sufficient factor VIII plasma levels (FVIII activity 1 h after administration). The course of aPTT and FVIII are shown in Fig. 1 .
After 3 weeks, the patient was discharged from the University Hospital without signs of recurrent haemorrhage or neurologic sequelae and with a stable haemoglobin value and was followed up in our outpatient facility. The immunosuppression was continuously tapered within a period of 3 months and the spontaneous FVIII residual activity rose to 57% three weeks after initiation of treatment. Two years after this episode, the patient is still in complete remission (FVIII residual activity 119%).
Early diagnosis and treatment of acquired haemophilia is essential for the reduction of morbidity and mortality. Although acquired haemophilia is a very rare condition, it should be suspected if an adult patient presents with severe spontaneous haemorrhage combined with an isolated prolonged aPTT that does not normalise in mixing studies. Subsequently, acquired haemophilia is confirmed by severely reduced or even undetectable levels of FVIII clotting activity with normal activity of the other coagulation factors of the intrinsic pathway (FIX, XI and XII). Mixing studies and measurements of the inhibitor titer are required for appropriate therapeutic management. Therefore, it is mandatory to refer such patients to specialised centres with the laboratory and clinical expertise in haemostasis. In the case described above, however, referral to a specialised centre took place as late as 13 days after admission without adequate diagnosis and treatment. This fact demonstrates the importance of continuous medical education on the cardinal symptoms of this serious disease in order to increase the level of suspicion.
Since various studies have described solid or haematologic malignancy or autoimmune disease as underlying condition in up to 60% of the cases, these concomitant diseases should be looked for [7] [8] [9] [10] . In our case, malignancy was excluded with sufficient probability. It is unclear whether the known and untreated chronic discoid lupus erythematodes is a predisposing factor for the development of acquired haemophilia A. Since rare cases of underlying non-systemic cutaneous diseases have been described in the literature [1, 2] , we assume that the discoid lupus in our patient might well be a predisposing disease.
By administration of high doses of rFVIIa, rapid haemostasis was achieved. Because of the severe bleeding complications threatening his limb function, we decided on a multimodal immunosuppression regimen consisting of steroids, cyclophosphamide and immunoadsorption in order to decrease the inhibitor titer rapidly. This combined aggressive strategy turned out to be successful in terms of reducing the inhibitor titer. This even allowed us very early in the post-surgical period to switch from a FVIII bypassing agent such as rFVIIa to FVIII replacement therapy. After tapering the dose of steroids and continuing cyclophosphamide, the patient's FVIII levels finally rose to 57% three weeks after initiating treatment. Thus, this combined treatment approach is suggested when rapid decrease in inhibitor titers is desired.
